Evoke Pharma Granted U.S. Patent for GIMOTI, Expanding Market Exclusivity

Evoke Pharma, Inc. received a Notice of Allowance from the USPTO for a U.S. patent application covering the use of GIMOTI® in patients with moderate to severe symptoms of gastroparesis. The patent is expected to expire in December 2036, providing market exclusivity for the non-oral treatment beyond existing patents. Evoke Pharma intends to list the patent in the FDA’s Orange Book and has filed another application for treatments in this patient population. GIMOTI is the only FDA-approved non-oral formulation of metoclopramide for diabetic gastroparesis, offering relief for symptoms associated with the condition.

Evoke Pharma is committed to supporting Gastroparesis Awareness Month in August to improve treatment options and awareness for patients with this chronic condition. Diabetic gastroparesis affects millions globally, causing serious gastrointestinal symptoms and complications due to delayed stomach emptying. GIMOTI is the only drug approved in the U.S. for gastroparesis, providing a non-oral, self-administered option for adults with acute and recurrent diabetic gastroparesis. Adverse reactions associated with GIMOTI include tardive dyskinesia (TD), extrapyramidal effects (EPS), and other potential side effects.

The company remains focused on maximizing the potential of GIMOTI as a patient-friendly treatment for diabetic gastroparesis. For more information, visit Evoke Pharma’s website and follow them on LinkedIn and Twitter. Evoke cautions that statements in this press release are forward-looking and subject to risks and uncertainties inherent in the business. Investors and media inquiries can contact Daniel Kontoh-Boateng at DKB Partners for more information.

Read more at GlobeNewswire: Evoke Pharma Receives Notice of Allowance for U.S. Patent